Organon, the global healthcare company formed through a spinoff from MSD, has announced its launch, with the goal to make a better and healthier every day for every woman. With a majority-female Leadership Team, the company will be headquartered in the US, with offices across the globe including one in Shoreditch, London.
Organon will be exploring new opportunities and partnerships across its three main pillars of women’s health, biosimilars and established brands:
- Women’s health
Organon has a dedicated team focusing on improving access to contraceptive and fertility products, and a comprehensive education and training programme to help women and healthcare professionals understand the choices available to them. There is a continued shift toward long-acting reversible contraceptives (LARCs) and a large fertility market with untapped potential driven by changing social demographics.
A dynamic market with multiple launch opportunities in the coming years, biosimilars will be a core area of growth with the potential to deliver value to both Organon, the NHS and patients in the UK.
- Established Brands
The Established Brands portfolio will be reinvigorated to maximise market-leading, well-known brands that span key therapy areas such as cardiovascular, respiratory, pain, bone and dermatology.
To mark the first day of trading, Organon gathered hundreds of voices from around the world to create the “Wall of Voices,” a multimedia installation outside the New York Stock Exchange, that symbolises Organon’s commitment to listening to the needs and challenges of women. The “Wall of Voices” shares powerful perspectives, voices, and images of women highlighting the health issues that are important to them.
Simon Nicholson, Managing Director of Organon UK&ENI Cluster (UK, Ireland, Israel, Sweden, Denmark, Norway, Finland, Latvia, Lithuania, Estonia & Iceland) said: “New acquisitions and partnerships will help Organon expand beyond our core strengths in contraceptives and fertility to meet the health needs of women at all stages of her life. This will be fuelled by a refreshed focus on our women’s health portfolio, further biosimilar launches, and a renewed energy put behind our trusted dermatology, pain, respiratory and cardiovascular brands.
“Our strength will come not only from our medicines and solutions but from the diverse team of Organon Founders we have gathered to launch this unique company. We are all personally invested in this opportunity and what we do really matters.”
Irina Spirieva, Commercial Operations Lead, Organon UK&ENI said: “For far too long women have been told to accept many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause. Organon’s mission is to change this. We believe that by identifying diseases earlier and modifying the course of diseases or health conditions, we can improve the quality of life for women at every stage of their lives.”
Anne Connolly, Women’s Health Lead at the Royal College of General Practitioners, is featured on the Wall of Voices and said: “The part that is overlooked is that women require personalised holistic care and her needs change during her life course. There is a lack of recognition of the impact her pregnancy, menstrual concerns, menopause symptoms may have not just on her physical wellbeing, but her psychological, sexual and social functioning.”